PTAB invalidates Medytox Botox patent
Novikov Alex / Shutterstock.com
An Ontario-based company has sued Allergan for allegedly infringing a method patent that protects the use of cosmetic drug Botox (onabotulinumtoxinA) to treat back pain.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Allergan, Botox, patent infringement, off-label use, patent